No Data
Ho\'s Ophthalmology: 2024 Annual Report
Ho\'s Ophthalmology: 2024 Annual Report Summary
Ho\'s Ophthalmology: First Quarter Report 2025
He Family Ophthalmology (301103.SZ) released its first-quarter results, with a net income of 32.5319 million yuan, an increase of 12.27%.
He’s Eye Hospital (301103.SZ) released the first quarter report for 2025, with the company's revenue of 2.91...
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
He Family Eye Hospital (301103.SZ) has not yet applied the ChatZOC ophthalmology large model.
On March 12, Gelonghui reported that He Family Ophthalmology (301103.SZ) stated on the investor interaction platform that the company has not yet applied the ChatZOC ophthalmology large model. The company has been closely monitoring the development of cutting-edge technologies in the ophthalmic field, including various advanced AI models. The privatization deployment of the DeepSeek model has been completed, and an AI assistant analysis is being introduced to the BI system platform. This matter has not caused significant impact on the company's current main business operations or performance. Meanwhile, the company is also actively exploring the application of other cutting-edge technologies, but when evaluating new technologies, it will fully consider their impact on the company's business processes and data.
Liaoning He Eye Hospital Group (SZSE:301103) Could Be Struggling To Allocate Capital
